USP9 (5G-02) Antibody sc-100628 from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

USP9 (5G-02) Antibody

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
USP9 (5G-02) Antibody

Santa Cruz Biotechnology, Inc.'s USP9 (5G-02) Antibody is a Mouse monoclonal antibody. The USP9 (5G-02) Antibody was generated using USP9X as the antigen. It reacts with Homo Sapiens, and Human. This antibody has been shown to work in applications such as: EIA, Immunoassay, Precipitation, ELISA, Immunofluorescence, Immunoprecipitation, and Western Blot.

Description

USP9 (5G-02)

Product Specs
ItemUSP9 (5G-02) Antibody
CompanySanta Cruz Biotechnology, Inc.
Price $333.00Supplier Page View Company Product Page
Catalog Numbersc-100628
NCBI Gene AliasesMRXS99F, FAM, hFAM, DFFRX, XLID99, MRX99, FAF
Antibody TypePrimary Antibodies
Quantity100 µg/ml
Clone5G-02
ApplicationsWB, IP, IF, ELISA
Reactivityhuman
ClonalityMonoclonal
Hostmouse
Conjugate/TagUnconjugated
FormatPurified
NCBI Full Gene Nameubiquitin specific peptidase 9 X-linked
TargetUSP9
IsotypeIgG1

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Elevated USP9X drives early-to-late-stage oral tumorigenesis via stabilisation of anti-apoptotic MCL-1 protein and impacts outcome in oral cancersBritish journal of cancerAugust 1, 2021Sulkshane P, Pawar SN, Waghole R, Pawar SS, Rajput P, Uthale A, Oak S, Kalkar P, Wani H, Patil R, et al.

(2) Cellular stress induces TRB3/USP9x-dependent Notch activation in cancerOncogeneFebruary 23, 2017Izrailit J, Jaiswal A, Zheng W, Moran MF, Reedijk M.

(3) Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymesChemistry & biologyNovember 23, 2011Altun M, Kramer HB, Willems LI, McDermott JL, Leach CA, Goldenberg SJ, Kumar KG, Konietzny R, Fischer R, Kogan E, et al.

(4) Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1Molecular cancer therapeuticsJuly 1, 2011Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, Dong XW, Hu YZ, Lin NM, He QJ, Yang B.

Be the First to Write a Review!